UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2022

Century Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-40498**	**84-2040295**
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

3675 Market Street **Philadelphia, Pennsylvania** (Address of principal executive offices)	**19104** (Zip Code)

Registrant's telephone number, including area code: **(267) 817-5790**

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	**Trading Symbol**	**Name of Exchange on Which Registered**
Common Stock, par value $0.0001 per share	**IPSC**	**Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On September 8, 2022, Century Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is being furnished herewith:

Exhibit No.	Document
99.1	Investor Presentation of Century Therapeutics, Inc., dated September 8, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By: /s/ Osvaldo Flores, Ph.D.
Name: Osvaldo Flores, Ph.D.
Title: President and Chief Executive Officer

Date: September 8, 2022

Exhibit 99.1

CENTURY THERAPEUTICS

Corporate Overview

September 2022



Forward-looking statements

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinica on the maintenance on certain key collaborative relat manufacturing and development of our product cand scope and likelihood of regulatory filings and approva regulatory approval of our product candidates; the im pandemic, geopolitical issues and inflation on our bus operations, supply chain and labor force; the performa in connection with the development of our product ca third parties conducting our future clinical trials as we suppliers and manufacturers; our ability to successfull product candidates and develop sales and marketing product candidates are approved; and our ability to m successfully enforce adequate intellectual property pr other risks and uncertainties are described more fully section of our most recent filings with the Securities a Commission and available at www.sec.gov. You should forward-looking statements as predictions of future e and circumstances reflected in our forward-looking st be achieved or occur, and actual results could differ m projected in the forward-looking statements. Moreove dynamic industry and economy. New risk factors and emerge from time to time, and it is not possible for m predict all risk factors and uncertainties that we may f required by applicable law, we do not plan to publicly forward-looking statements contained herein, whethe new information, future events, changed circumstanc

Emerging leader in cell therapies for cancer

Comprehensive iPSC cell platform
For immune effector cells

Technical Expertise
Genetic and protein engineering, process development and immuno-oncology

Foundation in Science
Continuing investment in innovation drives R&D

State-of-
manufact
Fully opera
improve
produ

Financial Strength
Cash runway into 2025, Ended 2Q22 with cash, cash equivalents, and investments of $429.4M

Emerging pipeline of candidates
Product engine anticipated to deliver 5 INDs over the next 3 years; CNTY-101 entering clinic 2H22

BMS Discovery Collaboration
Initial focus on AML (CNTY-104) and Multiple Myeloma (CNTY-106)

Employe
experien
and ent

Proven leadership team

Osvaldo (Lalo) Flores
CEO

novira THERAPEUTICS
Johnson & Johnson
MERCK

Hy Levitsky
President R&D

JUNO THERAPEUTICS
Roche

Adrienne Farid
COO

Greg Russotti
CTO

Celgene
MERCK

Luis Borges
CSO

Cell Medica
FivePrime
AMGEN

Michael Diem
CBO

CENTURY
THERAPEUTICS

Platform

Building a next generation allogeneic cell therapy pla

iPSC Reprogramming

- Comprehensive collection of clinical grade lines (CD34+ HSC, αβ T cell, γδ T cell derived)

Gene Editing

- Proprietary gene editing platform
  - CRISPR MAD7-derived gene editi
    precise transgene integration

iPSC Differentiation/Manufacturing

- Scalable protocols and processes to produce highly functional iNK and iT cell products

Protein Engineering

- Developing proprietary next-generatio
- Universal tumor targeting platform

Vertically integrated capabilities differentiate Century's approach

Foundational investments in iPSC know-how and manufacturing

FUJIFILM Value from Innovation

Cellular Dynamics

CENTURY THERAPEUTICS

iPSC license and collaboration agreement established in 2018

- Access to clinical grade iPSC lines
- Exclusive IP and know-how to generate immune effector cells using feeder-free methods (NK, T, Mac, DC)
- FCDI GMP manufacturing capacity for Century's product candidates
- Leveraging two decades of research & investment at University of Wisconsin and FCDI

Established in-house manufacturing accelerates learnings and enables fast product iteration

- 53,000 ft^2 facility
- Designed to produce multiple immune cell
- Two sites provides optionality and maximizes flexibility

Precision CRISPR MAD7 mediated sequential gene editing of iI generates uniform product candidates



Advantages of Century's Platfo

Precise CRISPR mediated homology d repair reduces off-target integration

Stepwise and efficient gene editing **av multiplex modification** and structural

Quality control through generation of homogenous MCB establishes genomi **integrity**

Manufacturing begins at the MCB, con be **free from genetic aberrations**

Allo-Evasion™ 1.0 designed to overcome 3 major pathways of h graft rejection



3 core edits disarm host cells fr eliminating therapy

1. Deletion of β2M, a protein required to HLA-1 on the cell surface prevents recc CD8 T cells
2. Knock out of CIITA eliminates HLA-II e escape elimination by CD4 T cells
3. Knock-in of HLA-E prevents killing by

Allo-Evasion™ 3.0 Provides Additional Protection Against NK C



4 core edits disarm host cells fr eliminating therapy

1. Deletion of β2M, a protein required to HLA-1 on the cell surface prevents recc CD8 T cells
2. Knock out of CIITA eliminates HLA-II e escape elimination by CD4 T cells
3. Knock-in of HLA-E prevents killing by
4. Knock-in of HLA-G prevents killing by

Expression of HLA-E + HLA-G further protects from NK killing

Proof-of-Concept Study with HLA-I Null K562 Cells Engineered with HLA-E and HLA-G



- HLA-E and HLA-G engage different receptors on NK cells including NKG2A, KIRs, and LIRs
- The expression of NKG2A, KIRs, and LIRs varies among NK cells from different donors

The Combination of HLA-E + HLA-G Im Protection to Killing by Allogeneic NI



Agglomerated Data from 22 NK Cell Donc



Illustrative potential of Allo-evasion™ on cellular pharmacokinetics and multiple doses

With Allo-Evasion™ engineering

Without Allo-Evasion™ engineering



Lack of durable responses seen to date in other allogeneic approaches likely due t
rejection of the product

Common progenitor milestone enables cost, time efficiencies



- iPSC cell bank with 12 core 3.0 gene edits introduced in 5 sequential steps
- Resets product development starting point: accelerates and de-risks development candidate selection

CENTURY
THERAPEUTICS

Discovery

iNK 3.0 common progenitor multiple new features for enhanced functionality



ENGINEERING PROFILE			
Step	**Gene Edit**		**Rationale**
1	KO	**NKG2A**	Potential to block inhibit
	KI	**IL15/IL15Ra**	Homeostatic cytokine s
2	KO	B2M	Allo-Evasion
	KI	HLA-E-2A-**HLA-G**	Allo-Evasion
3	KO	CIITA ex5	Allo-Evasion
	KI	**HSV-TK-2A-PSMA**	Safety switch + cell t
4	KO	**CD70**	Landing pad, potential to enha
	KI	**CD16-2A-NKG2D**	Ab targeting + Tumor stre
5	INS	CLYBL	Safe harbor site
	KI	CAR	Tumor targeting

Boldface: iNK 3.0-specific gene edits

Century's strategic vision for winning in solid tumors



Building best-in-class γδ iT cell platform with up to 5 distinct tumor killing mech

CENTURY
THERAPEUTICS

Pipeline and Franchises

Century's emerging franchises

B cell malignancies

CNTY-101: Lead product candidate, CD19 targeted CAR-iNK

- First product candidate to enter the clinic with edits designed to avoid 3 major pathways of rejection

CNTY-102: First γδ iT candidate, multi-specific (CD19 + CD79b) CAR-iT

Discovery pipeline: Leverages iNK 3.0 platform

Glioblastoma

CNTY-103: CD133 CAR iNK 3.0 for recurrent GBM

- Multi-tumor antigen targeting through combination approach addresses heterogeneity in GBM tumor cells

Discovery pipeline: Exploring iNK 3.0 and γδ iT platforms

Solid tumors

Future candidate:

- Expected to be ann
  2022

Discovery pipeline: Le
iT platform to target
challenging solid tum

Pipeline

Product candidate pipeline across cell platforms and targets in solid and hematologic cancers

Solid Tumors Hematologic Tumors

Product	iPSC Platform	Targets	Indications	Expected IND Submission	Discovery	Preclinical	Clinical
CNTY-101	iNK	CD19	B-Cell Malignancies	Mid 2022	IND clearance received		
CNTY-103	iNK	CD133	Glioblastoma	2024			
CNTY-102	iT	CD19 + CD79b	B-Cell Malignancies	2024			
CNTY-104	iNK/iT	Multi-specific	Acute Myeloid Leukemia	2024			
CNTY-106	iNK/iT	Multi-specific	Multiple Myeloma	2024			
Discovery Research Programs							
	iNK/iT	TBD	Solid Tumors	TBD			
	iNK	TBD	Hematological Tumors	2023			

CNTY-101: differentiated next-gen CD19 targeted prod

Highly differentiated profile

Allo-Evasion™ edits



CNTY-101

First cell product candidate designed to avoid all major pathways of host v graft rejection

ELIPSE-1: Phase 1 study vis

Explore 1 to 2 cycles* up to 6 doses wi LD conditioning

Effect of Allo-Evasion™ on iNK persist multiple doses

ELiPSE-1 trial to initiate imminently

Clinically meaningful and platform validating generated from ELiPSE-1 Schedule B



* Subject to FDA approval

Century's partnered programs

Bristol Myers Squibb brings complementary technologies and capabilities in competitive indications.

Bristol-Myers Squibb collaboration includes option to add 2 additional programs in either hematological malignancies or solid tumors.

Acute Myeloid Leukemia

CNTY-104: Multi-specific iT or iNK candidate

Potential for controlled dosing and persistence to eliminate blasts while mitigating toxicity to the marrow

Bristol Myers Squibb

Multiple Myeloma

CNTY-106: Multi-specifi candidate

Address relapses to cu therapies associated w to negative BCMA exp

Bristol Myers Sq

Anticipated catalysts over next 12 months

Underpinned by strong balance sheet with platform synergies a
operational excellence

CNTY-101

Becoming clinical stage biotech company with most advanced allogeneic cell therapy

- Phase 1 (ELiPSE-1) start in B-cell malignancies (2H22)

γδ iT Platform

Leveraging the comprehensive end-to-end platform

- γδ iT pre-clinical data (4Q22)

iNK 3.0 Common Progenitor

Creating platform efficiencies

- Select additional candidate based on iNK 3.0 (YE22) – disclose data at future medical meeting
- CNTY-103 development candidate (2023)

Disclosu

5 INDs anti next 3 years

- Solid tum expected announce

CENTURY
THERAPEUTICS

Thank you